Last updated: March 10, 2026
What is NDC 69584-0673?
NDC 69584-0673 refers to a specific brand or generic medication package. Based on the National Drug Code directory, this code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) type 1 in pediatric patients.
Market Overview
Disease Landscape and Patient Population
- Spinal Muscular Atrophy (SMA) affects approximately 1 in 8,000 to 10,000 live births.
- Estimated eligible patient population within the U.S.: approximately 350-400 new cases annually.
- SMA type 1 accounts for ~60% of SMA cases diagnosed in infancy.
Competitive Landscape
| Product |
Type |
Approval Year |
Indication |
Price (USD) |
| Zolgensma |
Gene therapy |
2019 |
SMA in pediatric patients |
$2.1 million (single dose) |
| Spinraza (nusinersen) |
Antisense oligonucleotide |
2016 |
SMA in pediatric/adult patients |
$750,000 for initial year, then ~$465,000/year |
| Evrysdi (risdiplam) |
Oral splice modifier |
2020 |
SMA in children and adults |
$340,000/year |
Regulatory and Market Access
- Pricing: Zolgensma costs approximately $2.1 million as a one-time infusion.
- Reimbursement: Usually covered by private insurers and Medicaid under value-based arrangements.
- Pricing Trends: Gene therapy prices trend upwards, driven by manufacturing complexity and therapy value assessments.
Market Projections
Sales Volume and Revenue
- Initial uptake: Estimated at 50-70 patients in the first year.
- Growth trajectory: Expected annual increase of 20-25% for the next 5 years, driven by expanding indications, increased diagnosis rates, and broader payer coverage.
| Year |
Projected Patients |
Revenue (USD million) |
Remarks |
| 2023 |
50 |
105 |
Current market launch |
| 2024 |
75 |
157.5 |
Payers broaden coverage |
| 2025 |
100 |
210 |
Growing awareness and diagnosis |
| 2026 |
125 |
262.5 |
Expansion to older SMA populations |
| 2027 |
150 |
315 |
Increased adoption and reimbursement |
Key Market Drivers
- Clinical efficacy of Zolgensma shows significant motor development improvement in SMA type 1.
- Regulatory approvals expanding to broader indications, including older patients.
- Pricing strategies emphasizing value-based models, encouraging broader access.
Challenges
- High upfront cost limits immediate adoption despite high perceived value.
- Manufacturing complexity affects supply chain stability.
- Competitive therapies could develop, especially oral options with similar efficacy.
Price Projections
- No significant price reduction is expected within the next 3-5 years due to high development and manufacturing costs.
- Payers may negotiate discounts or milestone-based payments, potentially reducing net prices.
- Price insensitivity may persist given the therapy's lifelong benefits and impact on quality of life.
| Scenario |
Assumption |
Projected Price (USD) per Dose |
Timeframe |
| Steady state |
No major price reduction; payment models shift toward value-based |
$2.1 million |
2023-2027 |
| Moderate discount |
Payers secure 10-15% discounts through negotiations |
$1.785–$1.785 million |
2023–2027 |
| Price reduction driven by policy |
Price drops to align with ambulatory gene therapies (~$1 million) |
~$1 million |
2025–2027 |
Policy and Reimbursement Landscape
- Payers favor value-based agreements for high-cost, one-time treatments.
- Health authorities like CMS are exploring outcomes-based payment models for gene therapies.
- Budget impact modeling influences formulary decisions, often favoring therapies demonstrating clinical superiority.
Summary
NDC 69584-0673 (Zolgensma) commands a premium price driven by high manufacturing costs and the rarity of SMA. Its market is constrained by the small patient population but benefits from high treatment efficacy. Sales are projected to grow at a compounded annual rate of 20% during the next five years, with steady pricing maintained under current models. Payer negotiations and policy reforms will influence future pricing trajectories.
Key Takeaways
- Zolgensma remains the only one-time gene therapy for SMA with a $2.1 million price tag.
- Market growth hinges on expanded diagnosis and broader age indications.
- Pricing stability expected; discounts and value-based arrangements could slightly lower net prices.
- Competitive pressures unlikely to significantly impact pricing in the near term.
- Reimbursement shifts toward outcome-based agreements will influence long-term pricing strategies.
FAQs
1. How does Zolgensma compare to other SMA treatments?
It offers a single-dose approach with demonstrated efficacy in infants, contrasting with Spinraza’s multiple dose regimen and Risdiplam’s daily oral administration, but at a higher initial cost.
2. What factors could reduce Zolgensma’s price?
Payer negotiations, development of alternative therapies, policy reforms, or increased competition could lead to price reductions.
3. How many patients are eligible for Zolgensma annually?
Approximately 350-400 new SMA cases are diagnosed each year in the U.S., with a significant portion being SMA type 1 infants eligible for Zolgensma.
4. What is the potential for global expansion?
Market entry depends on regulatory approvals, local healthcare budgets, and access policies, with European and Asian markets gradually adopting gene therapies.
5. How sustainable is the high-cost model for gene therapies?
Long-term sustainability depends on outcomes-based reimbursement models and the therapies’ lifetime benefits versus their high initial price.
References
[1] U.S. Food and Drug Administration. (2019). Zolgensma (onasemnogene abeparvovec-xioi) for intravenous use. FDA Approval Summary.
[2] IQVIA. (2022). Global Trends in Biologic and Gene Therapy Pricing.
[3] EvaluatePharma. (2022). World Liver Disease Market Analysis.
[4] CMS. (2022). Proposal for Outcomes-Based Payments for High-Cost Treatments.
Note: The specific NDC corresponds to Zolgensma based on the provided code. Verify code-to-product mappings with current FDA and pharmacy records.
